drugset / Trial / NCT05312216
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, open-label study to evaluate the efficacy and safety of Durvalumab plus Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma.
Timeline
- Start
- 2023-04
- Primary completion
- 2024-03
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Lenvatinib | Small molecule | 8 mg | — |
| Subject | Lenvatinib | Small molecule | 12 mg | — |